stock downgrade William Blair Downgrades Lucira Health to Market Perform As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022. Roche to Acquire GenMark Diagnostics for $1.8B Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share. Oppenheimer Downgrades Invitae to Perform Rating Although Oppenheimer raised its price target from $48 to $51 in early January, the investment firm sees "increased risk of underperformance for Invitae shares." Evercore ISI Downgrades Twist Bioscience to In-Line Rating The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear. BTIG Downgrades Fulgent Genetics from Buy to Neutral The investment bank said it expects demand for Fulgent's COVID-19 testing to decline over the next two years. Oct 14, 2020 JP Morgan Rates Invitae Neutral Oct 1, 2020 Amid Volatile Markets, GenomeWeb Index Up 3 Percent in September Sep 22, 2020 UBS Downgrades Illumina to Neutral; Expresses Doubts About Grail Deal Jul 1, 2020 OncoCyte Downgraded to Neutral by Piper Sandler on Unsuccessful Results for Lung Cancer Test Feb 3, 2020 Illumina Stock Drags GenomeWeb Index Down in January Jan 2, 2020 Qiagen Stock Tanks in December, Fluidigm Shares Soar as GenomeWeb Index Ends 2019 on High Note Jan 2, 2020 Evercore ISI Upgrades PerkinElmer, Downgrades Hologic Jan 2, 2020 Illumina Stock Downgraded to 'In-Line' by Evercore ISI Dec 11, 2019 GenMark Diagnostics Downgraded by JP Morgan to Neutral Oct 9, 2019 Waters Stock Downgraded by Barclays Sep 27, 2019 Luminex, Accelerate Diagnostics Downgraded by JP Morgan to Underweight Jul 16, 2019 Qiagen Stock Downgraded to 'In Line' by Evercore ISI Jul 9, 2019 Cowen Downgrades Myriad Genetics' Stock Jan 5, 2018 William Blair Downgrades Illumina to Market Perform Dec 13, 2017 JP Morgan Downgrades Genomic Health to Underweight Oct 12, 2017 Cowen Downgrades NanoString to Market Perform on Preannouncement of 'Huge Q3 Miss' May 3, 2017 Raymond James Downgrades Genomic Health to Market Perform Apr 19, 2017 Cantor Fitzgerald Downgrades PerkinElmer to Neutral Jan 4, 2017 Barclays Upgrades Agilent, Downgrades Bruker Aug 4, 2016 PerkinElmer Q2 Revenues Up 2 Percent; Discloses Bioo Scientific Acquisition Load More Breaking News Pediatric Medulloblastoma Subgroups May Benefit from Lower-Dose Radiation Therapy Space Radiation Shows Limited Effects on Mammalian Sperm DNA, Fertility Bluestar Genomics Sues Former Consultant, Ludwig Institute for Cancer Research Over IP Ownership New Products Posted to GenomeWeb: 10x Genomics, Swift Biosciences, Agilent Technologies, More In Brief This Week: Quantum-Si, TGen, Yale, and More People in the News: New Appointments at Invitae, PGDx, Oxford Nanopore, PacBio, More The Scan Fertility Fraud Found Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today. Ties Between Vigorous Exercise, ALS in Genetically At-Risk People Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports. Test Warning The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK. Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.